Notably, E. coli OMVs synergize with anti-PD-1 checkpoint inhibitors by promoting the recruitment of stem-like CD8+ T cells into the tumor microenvironment, achieving significant tumor growth suppression in preclinical models [93]. This evidence concerns the gene CD8A and neoplasm.